Avenge Bio is an oncology-focused biotechnology company developing transformative cell-based immunotherapeutic products for the treatment of intractable solid tumors by incorporating its LOCOcyte platform. The LOCOcyte platform leverages proprietary engineered cells delivered to the local tumor environment that generate high concentrations of immune effector molecules in proximity to the tumor.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/02/22 | $45,000,000 | Series A |
CAM Capital Longitude Capital Pappas Capital Perceptive Advisors Rock Springs Capital | undisclosed |
